Physician profile
Frances Dilley
NPI 1508816950
$1,050.28
in general payments reported to CMS, 2019-2025
20 companies · $567 in 2025
The $567 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $39.93 · 2021: $114 · 2024: $153 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $720.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $288.39 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $171.90 | 2025 | Korlym |
| Seagen INC. | $101.60 | 2021 | |
| Lilly USA, LLC | $74.87 | 2019-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $58.44 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $47.20 | 2025 | Voquezna |
| Abbott Laboratories | $42.85 | 2024-2025 | Freestyle Libre 3 |
| Nevro Corp. | $35.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $30.84 | 2019-2024 | |
| Abbvie INC. | $28.35 | 2020 | |
| Astellas Pharma US INC | $24.91 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $21.91 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.72 | 2019 | |
| Photonicare INC | $19.13 | 2025 | Otosight Middle Ear Scope |
| Radius Health, INC. | $16.63 | 2024 | Tymlos |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $16.19 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.25 | 2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.80 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.04 | 2021 | |
| Exeltis, USA INC. | $11.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Dilley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.